Financing ·
Absci Corporation entered into an underwriting agreement on June 24, 2026, to issue and sell 13,495,277 shares of…
ABSIAbsci Corp
Absci Corporation entered into an underwriting agreement on June 24, 2026, to issue and sell 13,495,277 shares of common stock at $7.41 per share. The company expects to net approximately $93.5 million to fund the advancement of its AI-designed anti-PRLR antibody product candidate, ABS-201, for androgenetic alopecia and endometriosis, and for general corporate purposes. Absci Corp is a biotechnology company focused on developing AI-designed antibody products.